Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion

Alfayez, 2018, Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges, Expert Rev. Hematol., 11, 373, 10.1080/17474086.2018.1459184 Baell, 2010, New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays, J. Med. Chem., 53, 2719, 10.1021/jm901137j Barbieri, 2017, Promoter-bound METTL3 maintains myeloid leukaemia by m(6)A-dependent translation control, Nature, 552, 126, 10.1038/nature24678 Beatty, 2015, Immune escape mechanisms as a guide for cancer immunotherapy, Clin. Cancer Res., 21, 687, 10.1158/1078-0432.CCR-14-1860 Berger, 2008, Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies, Clin. Cancer Res., 14, 3044, 10.1158/1078-0432.CCR-07-4079 Boccaletto, 2018, MODOMICS: a database of RNA modification pathways. 2017 update, Nucleic Acids Res., 46, D303, 10.1093/nar/gkx1030 Burris, 1998, Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies, Invest. New Drugs, 16, 19, 10.1023/A:1016066529642 Campeau, 2009, A versatile viral system for expression and depletion of proteins in mammalian cells, PLoS One, 4, e6529, 10.1371/journal.pone.0006529 Chen, 2012, Development of cell-active N6-methyladenosine RNA demethylase FTO inhibitor, J. Am. Chem. Soc., 134, 17963, 10.1021/ja3064149 Chen, 2018, Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity, J. Clin. Invest., 128, 5647, 10.1172/JCI97570 Cho, 2016, PEG-b-PLA micelles and PLGA-b-PEG-b-PLGA sol-gels for drug delivery, J. Control. Release, 240, 191, 10.1016/j.jconrel.2015.12.015 Cowan, 1986, Phase II trial of bisantrene in patients with advanced sarcoma: a Southwest Oncology Group Study, Cancer Treat. Rep., 70, 685 Daver, 2019, Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study, Cancer Discov., 9, 370, 10.1158/2159-8290.CD-18-0774 de Forni, 1993, Phase I and pharmacokinetic study of brequinar (DUP 785; NSC 368390) in cancer patients, Eur. J. Cancer, 29A, 983, 10.1016/S0959-8049(05)80206-0 Deng, 2018, LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration, Nature, 562, 605, 10.1038/s41586-018-0615-z Deng, 2018, Role of N(6)-methyladenosine modification in cancer, Curr. Opin. Genet. Dev., 48, 1, 10.1016/j.gde.2017.10.005 Deng, 2018, RNA N(6)-methyladenosine modification in cancers: current status and perspectives, Cell Res., 28, 507, 10.1038/s41422-018-0034-6 Dobin, 2013, STAR: ultrafast universal RNA-seq aligner, Bioinformatics, 29, 15, 10.1093/bioinformatics/bts635 Dombret, 2015, International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts, Blood, 126, 291, 10.1182/blood-2015-01-621664 Dong, 2002, Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, Nat. Med., 8, 793, 10.1038/nm730 Dull, 1998, A third-generation lentivirus vector with a conditional packaging system, J. Virol., 72, 8463, 10.1128/JVI.72.11.8463-8471.1998 Friesner, 2004, Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy, J. Med. Chem., 47, 1739, 10.1021/jm0306430 Frye, 2018, RNA modifications modulate gene expression during development, Science, 361, 1346, 10.1126/science.aau1646 Gao, 2017, Stereoselective stabilization of polymeric vitamin E conjugate micelles, Biomacromolecules, 18, 4349, 10.1021/acs.biomac.7b01409 Gopalakrishnan, 2018, Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients, Science, 359, 97, 10.1126/science.aan4236 Han, 2019, Anti-tumour immunity controlled through mRNA m(6)A methylation and YTHDF1 in dendritic cells, Nature, 566, 270, 10.1038/s41586-019-0916-x He, 2015, Identification of a novel small-molecule binding site of the fat mass and obesity associated protein (FTO), J. Med. Chem., 58, 7341, 10.1021/acs.jmedchem.5b00702 Hirayama, 1999, Cyclodextrin-based controlled drug release system, Adv. Drug Deliv. Rev., 36, 125, 10.1016/S0169-409X(98)00058-1 Hu, 2009, ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays, J. Immunol. Methods, 347, 70, 10.1016/j.jim.2009.06.008 Huang, 2020, m(6)A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer, Cancer Cell, 37, 270, 10.1016/j.ccell.2020.02.004 Huang, 2020, RNA modifications in cancer: functions, mechanisms, and therapeutic implications, Annu. Rev. Cancer Biol., 4, 221, 10.1146/annurev-cancerbio-030419-033357 Huang, 2019, Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia, Cancer Cell, 35, 677, 10.1016/j.ccell.2019.03.006 Huang, 2015, Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5, Nucleic Acids Res., 43, 373, 10.1093/nar/gku1276 Huth, 2005, ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens, J. Am. Chem. Soc., 127, 217, 10.1021/ja0455547 Issa, 2004, Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies, Blood, 103, 1635, 10.1182/blood-2003-03-0687 Jafari, 2014, The cellular thermal shift assay for evaluating drug target interactions in cells, Nat. Protoc., 9, 2100, 10.1038/nprot.2014.138 Jia, 2013, Reversible RNA adenosine methylation in biological regulation, Trends Genet., 29, 108, 10.1016/j.tig.2012.11.003 Jia, 2011, N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO, Nat. Chem. Biol., 7, 885, 10.1038/nchembio.687 Kang, 2016, Inhibitory leukocyte immunoglobulin-like receptors: immune checkpoint proteins and tumor sustaining factors, Cell Cycle, 15, 25, 10.1080/15384101.2015.1121324 Krause, 2007, Right on target: eradicating leukemic stem cells, Trends Mol. Med., 13, 470, 10.1016/j.molmed.2007.09.003 Krivtsov, 2006, Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9, Nature, 442, 818, 10.1038/nature04980 Ley, 2013, Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia, N. Engl. J. Med., 368, 2059, 10.1056/NEJMoa1301689 Li, 2011, RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome, BMC Bioinformatics, 12, 323, 10.1186/1471-2105-12-323 Li, 2014, SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells, Cell Stem Cell, 15, 431, 10.1016/j.stem.2014.08.001 Li, 2015, Overexpression and knockout of miR-126 both promote leukemogenesis, Blood, 126, 2005, 10.1182/blood-2015-04-639062 Li, 2017, FTO plays an oncogenic role in acute myeloid leukemia as a N(6)-methyladenosine RNA demethylase, Cancer Cell, 31, 127, 10.1016/j.ccell.2016.11.017 Lipinski, 2004, Lead- and drug-like compounds: the rule-of-five revolution, Drug Discov. Today Technol., 1, 337, 10.1016/j.ddtec.2004.11.007 Liu, 2016, A selective small molecule DNA2 inhibitor for sensitization of human cancer cells to chemotherapy, EBioMedicine, 6, 73, 10.1016/j.ebiom.2016.02.043 Lomenick, 2009, Target identification using drug affinity responsive target stability (DARTS), Proc. Natl. Acad. Sci. U S A, 106, 21984, 10.1073/pnas.0910040106 Mauer, 2019, FTO controls reversible m(6)Am RNA methylation during snRNA biogenesis, Nat. Chem. Biol., 15, 340, 10.1038/s41589-019-0231-8 Miller, 1986, A phase II study of bisantrene in malignant lymphomas. A Southwest Oncology Group Study, Cancer Chemother. Pharmacol., 16, 67, 10.1007/BF00255289 Myers, 1984, Phase II clinical trial with bisantrene in patients with advanced refractory small cell lung cancer, Cancer Treat. Rep., 68, 927 Niu, 2019, RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3, Mol. Cancer, 18, 46, 10.1186/s12943-019-1004-4 Noe, 1990, Phase I and pharmacokinetic study of brequinar sodium (NSC 368390), Cancer Res., 50, 4595 Ohlsson, 2014, Initiation of MLL-rearranged AML is dependent on C/EBPalpha, J. Exp. Med., 211, 5, 10.1084/jem.20130932 Orskov, 2015, Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: a rationale for combined targeting of PD-1 and DNA methylation, Oncotarget, 6, 9612, 10.18632/oncotarget.3324 Padariya, 2016, Structure-based design and evaluation of novel N-phenyl-1H-indol-2-amine derivatives for fat mass and obesity-associated (FTO) protein inhibition, Comput. Biol. Chem., 64, 414, 10.1016/j.compbiolchem.2016.09.008 Patnaik, 2015, Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors, Clin. Cancer Res., 21, 4286, 10.1158/1078-0432.CCR-14-2607 Peters, 1992, In vitro and in vivo studies on the combination of Brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridine, Br. J. Cancer, 65, 229, 10.1038/bjc.1992.46 Pollyea, 2017, Therapeutic targeting of acute myeloid leukemia stem cells, Blood, 129, 1627, 10.1182/blood-2016-10-696039 Pratt, 1986, Phase I clinical and pharmacokinetic study of bisantrene in refractory pediatric solid tumors, Invest. New Drugs, 4, 149, 10.1007/BF00194594 Rothman, 2017, The rediscovery of bisantrene: a review of the literature, Int. J. Cancer Res. Ther., 2, 1 Salmon, 2007, Production and titration of lentiviral vectors, Curr. Protoc. Hum. Genet., 10.1002/0471142905.hg1210s54 Sanjana, 2014, Improved vectors and genome-wide libraries for CRISPR screening, Nat. Methods, 11, 783, 10.1038/nmeth.3047 Schwartsmann, 1990, Phase I study of brequinar sodium (NSC 368390) in patients with solid malignancies, Cancer Chemother. Pharmacol., 25, 345, 10.1007/BF00686235 Singh, 2016, Important role of FTO in the survival of rare panresistant triple-negative inflammatory breast cancer cells facing a severe metabolic challenge, PLoS One, 11, e0159072, 10.1371/journal.pone.0159072 Stahl, 2019, Immune checkpoint inhibitors in acute myeloid leukemia: novel combinations and therapeutic targets, Curr. Oncol. Rep., 21, 37, 10.1007/s11912-019-0781-7 Stewart, 2003, Lentivirus-delivered stable gene silencing by RNAi in primary cells, RNA, 9, 493, 10.1261/rna.2192803 Su, 2018, R-2HG exhibits anti-tumor activity by targeting FTO/m(6)A/MYC/CEBPA signaling, Cell, 172, 90, 10.1016/j.cell.2017.11.031 Subramanian, 2005, Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, Proc. Natl. Acad. Sci. U S A, 102, 15545, 10.1073/pnas.0506580102 Tang, 2019, The role of the fat mass and obesity-associated protein in the proliferation of pancreatic cancer cells, Oncol. Lett., 17, 2473 Thorvaldsdottir, 2013, Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration, Brief. Bioinform., 14, 178, 10.1093/bib/bbs017 Toh, 2015, A strategy based on nucleotide specificity leads to a subfamily-selective and cell-active inhibitor of N6-methyladenosine demethylase FTO, Chem. Sci., 6, 112, 10.1039/C4SC02554G Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N. Engl. J. Med., 366, 2443, 10.1056/NEJMoa1200690 Vu, 2017, The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells, Nat. Med., 23, 1369, 10.1038/nm.4416 Wang, 2015, Fluorescein derivatives as bifunctional molecules for the simultaneous inhibiting and labeling of FTO protein, J. Am. Chem. Soc., 137, 13736, 10.1021/jacs.5b06690 Wang, 2014, N6-methyladenosine-dependent regulation of messenger RNA stability, Nature, 505, 117, 10.1038/nature12730 Wei, 2018, Differential m(6)A, m(6)Am, and m(1)A demethylation mediated by FTO in the cell nucleus and cytoplasm, Mol. Cell, 71, 973, 10.1016/j.molcel.2018.08.011 Weng, 2018, METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m(6)A modification, Cell Stem Cell, 22, 191, 10.1016/j.stem.2017.11.016 Wunderlich, 2013, AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model, Blood, 121, e90, 10.1182/blood-2012-10-464677 Yang, 2014, Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents, Leukemia, 28, 1280, 10.1038/leu.2013.355 Yang, 2019, m(6)A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade, Nat. Commun., 10, 2782, 10.1038/s41467-019-10669-0 Yap, 1983, Bisantrene, an active new drug in the treatment of metastatic breast cancer, Cancer Res., 43, 1402 Ye, 2015, Hematopoietic differentiation is required for initiation of acute myeloid leukemia, Cell Stem Cell, 17, 611, 10.1016/j.stem.2015.08.011 Yun, 2016, Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials, Clin. Epigenetics, 8, 68, 10.1186/s13148-016-0233-2 Zhang, 2019, Structural insights into FTO's catalytic mechanism for the demethylation of multiple RNA substrates, Proc. Natl. Acad. Sci. U S A, 116, 2919, 10.1073/pnas.1820574116 Zhang, 2015, Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway, Mol. Cancer, 14, 56, 10.1186/s12943-015-0326-0 Zheng, 2014, Synthesis of a FTO inhibitor with anticonvulsant activity, ACS Chem. Neurosci., 5, 658, 10.1021/cn500042t Zheng, 2013, ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility, Mol. Cell, 49, 18, 10.1016/j.molcel.2012.10.015